Adcetris survival data mature amid ongoing tox concerns
This article was originally published in Scrip
Executive Summary
Takeda's Millennium unit and partner Seattle Genetics have reported significant three-year survival follow-up data for their antibody-drug conjugate (ADC) product, Adcetris (brentuximab vedotin) in relapsed or refractory Hodgkin's lymphoma (HL) from its pivotal Phase II study. The data come as a boost for the product's efficacy, at least, while doubts swirl over its safety profile.